In prostate cancer, elevated SOX11 could suppress the invasive and migrative abilities of prostate cancer cells in vitro (Yao et al., 2015), and SOX11 promoter hypermethylation was correlated to adverse clinicopathological properties (Pugongchai, Bychkov, & Sampatanukul, 2017). This evidence concerns the gene SOX11 and Familial prostate cancer.